Table 3.
Main ongoing clinical trials with ICI/RT combinations in advanced HNSCC.
| Trial Name | Study Phase | Enrollment | Stage | Experimental/Control Arm | Status |
|---|---|---|---|---|---|
| NCT03380394 | Phase II | 122 | III | RT + pembrolizumab vs. RT + cisplatin | Recruiting |
| NCT03673735 | Phase III | 650 | III | RT + cisplatin +/− durvalumab HPV-negative HNSCC only | Not yet recruiting |
| NCT02999087 | Phase III | 688 | III | RT + cisplatin vs. RT + cetuximab vs. RT + cetuximab + avelumab | Recruiting |
| NCT03349710 | Phase III | 1046 | III/IV | RT + cetuximab +/− nivolumab vs. RT + cisplatin +/− nivolumab | Recruiting |
| NCT03426657 | Phase II | 120 | III | RT + durvalumab + tremelimumab | Not yet recruiting |